

Date: March 29, 2025

BSE Limited

1st Floor, New Trading Ring,
Rotunda Building, P.J. Towers,
Dalal Street, Fort, Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Sub: Disclosure under Regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).

Ref: Effective date of the Scheme of Arrangement for Amalgamation amongst Shree Jee Laboratory Private Limited (“Transferor Company 1”), JPR Labs Private Limited (“Transferor Company 2”) and Jaspack Industries Private Limited (“Transferor Company 3”) with Mankind Pharma Limited (“Transferee Company”/ “the Company”).

Dear Sir/Madam,

In continuation of our earlier communication dated February 27, 2025, wherein it was informed that the Hon’ble National Company Law Tribunal, New Delhi Bench (‘NCLT’), vide its Order dated February 25, 2025, (“Order”) (certified copy of which was received on March 12, 2025) had approved the Scheme of Arrangement for Amalgamation of Shree Jee Laboratory Private Limited (“Transferor Company 1”), JPR Labs Private Limited (“Transferor Company 2”) and Jaspack Industries Private Limited (“Transferor Company 3”) with Mankind Pharma Limited (“Transferee Company”/ “the Company”) and their Respective Shareholders and Creditors (“Scheme”) under the provisions of Sections 230 to 232 and other applicable provisions of the Companies Act, 2013 (“Act”) read with the Rules framed thereunder.

In continuation of the same, we wish to inform that each of the Transferor Companies and the Transferee Company have filed E-Form INC-28 with the concerned Registrar of Companies (“ROC”) today i.e. March 29, 2025 for determining the effective date of the Scheme of Arrangement. Accordingly, in term of Clause 1.7 of Part I of the Scheme, the Effective Date of the Scheme is March 29, 2025, being the date on which the certified copy of the order of the NCLT sanctioning the said Scheme is filed with the ROC. Consequently, the Transferor Companies stands amalgamated into the Company and be dissolved without being wound up w.e.f. March 29, 2025. Further, pursuant to clause 3 and 4 of Part II of the Scheme, all the Assets and Liabilities of the Transferor Companies stands transferred to the Transferee Company.

Furthermore, with effect from the Effective Date, as per Clause 2.1 of Part-III of the Scheme the Authorized Share Capital of Transferor Companies stands clubbed with that of the

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com



Transferee Company and the Memorandum of Association of the Company stands amended as follows:

“The Authorised Share Capital of the Company is Rs. 4,21,51,00,000/- (Rupees Four Hundred Twenty One Crores Fifty One Lakhs Only) divided into 227,78,60,000 (Two Hundred Twenty Seven Crores Seventy Eight Lakhs Sixty Thousand) Equity Shares of Re. 1/- (Rupee One) each and 19,37,24,000 (Nineteen Crores Thirty Seven Lakhs Twenty Four Thousand) 0.01% Optionally Convertible Non-Cumulative Redeemable Preference Shares of Rs. 10/- (Rupees Ten) each.”

Kindly take note of the above Updation and oblige.

Thanking you,

Yours faithfully,
For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary and Compliance Officer